1. Among patients with locally advanced head and neck squamous-cell carcinoma (HNSCC), neoadjuvant and adjuvant pembrolizumab improved event-free survival compared...

1. In this randomized trial, among patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slowed the decline in the forced vital...

1. In patients with myasthenia gravis (MG) who had anti-acetylcholine receptor antibodies or anti-muscle-specific kinase antibodies, intravenous inebilizumab reduced disease...

1. In this randomized controlled trial of patients with pulmonary arterial hypertension (PAH) and high risk of mortality, sotatercept reduced...

1. In this randomized controlled trial of patients with posterior circulation stroke not for thrombectomy, treatment with alteplase 4.5 to...

1. In this randomized controlled trial of patients with nonrelapsing secondary progressive multiple sclerosis (SPMS), oral tolebrutinib reduced the risk...

1. In this randomized controlled trial of patients with symptomatic paroxysmal atrial fibrillation, pulsed field ablation (PFA) was noninferior to...

1. Lepodisiran, a long-duration small interfering RNA targeting lipoprotein(a) synthesis, reduced serum concentrations of lipoprotein(a) compared to placebo in adults...

1. Among patients with type-2 diabetes (T2D) requiring insulin therapy, automated insulin delivery (AID) resulted in a greater reduction in...

1. In this randomized controlled trial, inebilizumab, an anti-CD19 monoclonal antibody, reduced the risk of flares and increased the likelihood...